Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $70 price target.
CleanSpark Stock Climbs On Strong Q1 Results
The company reported quarterly sales of $73.79 million, beating the analyst consensus estimate of $70.41 million by 4.79% and representing a 165.24% increase over sales of $27.82 million year-over-year. CleanSpark also reported its current hashrate surpasses 12.5 EH/s
